Lindsay Androski serves as Executive at Arbutus Biopharma Corp, where they oversee executive responsibilities. Since joining the company, Lindsay Androski has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Feb 2, 2026 involved receiving (via award) 71,700 shares valued at $0.
Lindsay Androski currently holds 71,700 shares of Arbutus Biopharma Corp (ABUS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Lindsay Androski has been a net neutral trader of ABUS stock. They have purchased $0 and sold $0 worth of shares.
Lindsay Androski's most recent insider trade was on Feb 2, 2026, when they sold 71,700 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |